Legislative Efforts to Control Prescription Drug Prices
This memorandum summarizes legislative efforts since 2017 to control prescription drug prices. It includes information on both bills that failed as well as those that became law.
Second Regular Session | 74th General Assembly
Colorado General AssemblyThis memorandum summarizes legislative efforts since 2017 to control prescription drug prices. It includes information on both bills that failed as well as those that became law.
During the 2017 legislative session, the General Assembly considered measures on environmental matters, public health care issues, and certificates and licenses. The bills and resolutions described below passed and became law, unless otherwise noted.
During the 2017 legislative session, the General Assembly considered several measures related to Medicaid, insurance carriers, and substance use disorder in Colorado. The General Assembly also considered measures related to background checks for some types of providers and made changes to the...
Final Report to the Colorado General Assembly by the Opioid and Other Substance Use Disorders Interim Study Committee.
This memorandum addresses patient access to experimental treatments, including access to clinical trials, participation in the U.S. Food and Drug Administration’s Expanded Access (Compassionate Use) Program, and access to treatments under Colorado’s Right to Try Act. Additionally, this...
This issue brief addresses the state’s emergency mental health hold procedure, which allows for a person to be involuntarily held for a 72-hour period of treatment and evaluation if he or she appears to have a mental illness and, due to the mental illness, appears to be an imminent danger to...
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorder Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance use Disorders Interim Study Committee at its September 2017 meeting.